You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

homologous recombination deficiency

Showing 1 - 25 of 3,779
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • Homologous Recombination Deficiency
  • (no location specified)
Oct 18, 2023

Ovarian Cancer Trial in Pittsburgh (Olaparib tablet)

Not yet recruiting
  • Ovarian Cancer
  • Olaparib tablet
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Nov 1, 2023

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

Not yet recruiting
  • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery Fudan University Shanghai Caner
Feb 22, 2023

Homologous Recombination Deficiency, Triple Negative Breast Cancer Trial (Niraparib)

Not yet recruiting
  • Homologous Recombination Deficiency
  • Triple Negative Breast Cancer
  • (no location specified)
Jul 15, 2022

HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Completed
  • Epithelial Ovarian Cancer
  • +6 more
  • Evaluation of homologous recombination deficiency score
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Recruiting
  • Lung Cancer
    • Shanghai, China
      Shanghai Chest Hospital
    Jul 20, 2023

    Breast Cancer Trial in Amsterdam (carboplatin, thiotepa, and cyclophosphamide, chemo (docetaxel, doxorubicin, cyclofosfamide,

    Recruiting
    • Breast Cancer
    • carboplatin, thiotepa, and cyclophosphamide
    • chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
    • Amsterdam, Netherlands
      NKI-AVL
    Mar 21, 2022

    Castration-resistant Prostate Cancer, Homologous Recombination Deficiency Trial in Sydney (Testosterone Enanthate 100 MG/ML

    Recruiting
    • Castration-resistant Prostate Cancer
    • Homologous Recombination Deficiency
    • Testosterone Enanthate 100 MG/ML Injectable Solution
    • Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
    • Sydney, New South Wales, Australia
      Kinghorn Cancer Centre, St. Vincent's Hospital
    Dec 16, 2022

    Breast Cancer Trial in Spain (Olaparib)

    Terminated
    • Breast Cancer
    • Barcelona, Spain
    • +7 more
    Jan 18, 2023

    Homologous Recombination Deficiency in Chinese Ovarian Cancer

    Not yet recruiting
    • Ovarian Cancer
    • +2 more
    • PARP inhibitor
    • Nanjing, Jiangsu, China
      Xiaoxiang Chen, MD,PhD
    Sep 4, 2021

    Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) Trial in Worldwide

    Terminated
    Has Results
    • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    • Homologous Recombination Deficiency (HRD)
    • Athens, Georgia
    • +8 more
    Oct 20, 2021

    Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

    Recruiting
    • Metastatic Castration-resistant Prostate Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Apr 7, 2022

    Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

    Active, not recruiting
    • Advanced Breast Cancer
    • +2 more
    • Talazoparib Tosylate
    • Stanford, California
      Stanford University Hospitals and Clinics
    Nov 16, 2022

    Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)

    Recruiting
    • Castration-Resistant Prostate Carcinoma
    • Prostate Adenocarcinoma
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 23, 2022

    Solid Tumor, Adult Trial in Miami (Pembrolizumab 200 mg Q3W)

    Active, not recruiting
    • Solid Tumor, Adult
    • Pembrolizumab 200 mg Q3W
    • Miami, Florida
      Miami Cancer Institute at Baptist Health, Inc.
    Nov 18, 2022

    Homologous Recombination Deficiency Among Newly Diagnosed,

    Recruiting
    • Fallopian Tube Cancer
      • Arkhangelsk, Russian Federation
      • +24 more
      Jul 18, 2022

      Solid Tumor, Adult, Homologous Recombination Deficiency Trial in Washington, Hackensack, Charlotte (Niraparib, Carboplatin)

      Recruiting
      • Solid Tumor, Adult
      • Homologous Recombination Deficiency
      • Washington, District of Columbia
      • +2 more
      Aug 31, 2021

      A Training Set for the HRD Model in EOC

      Recruiting
      • Epithelial Ovarian Cancer
      • +5 more
      • Homologous recombination deficiency model
      • Beijing, Beijing, China
        Lei Li
      Dec 2, 2020

      Mesothelioma, Homologous Recombination Deficiency Trial in Chicago (Olaparib)

      Recruiting
      • Mesothelioma
      • Homologous Recombination Deficiency
      • Chicago, Illinois
        University of Chicago Medical Center
      May 12, 2021

      Ovarian Tumor Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation Trial in Groningen, Leiden, Rotterdam (Functional

      Recruiting
      • Ovarian Neoplasm Epithelial
      • +3 more
      • Functional RAD51 assay
      • Olaparib Oral Product
      • Groningen, Netherlands
      • +2 more
      Mar 30, 2021

      Breast Cancer, Breast Cancer Metastatic Trial in Spain (Niraparib 100 MG, Aromatase Inhibitors)

      Terminated
      • Breast Cancer
      • Breast Cancer Metastatic
      • Niraparib 100 MG
      • Aromatase Inhibitors
      • A Coruña, Spain
      • +9 more
      Jan 17, 2023

      Advanced Cancers Trial in Boston (LY2606368)

      Active, not recruiting
      Has Results
      • Advanced Cancers
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Jan 18, 2022

      Homologous Recombination Inquiry Through Ovarian Malignancy

      Completed
      • Ovarian Cancer
      • +2 more
        • Niigata city, Niigata Prefecture, Japan
          Niigata University Graduate School of Medical and Dental Science
        Jan 19, 2023

        Advanced Malignant Tumor, Breast Cancer, Ovarian Cancer Trial in United States (AMXI-5001:Dose Escalation Phase I,

        Recruiting
        • Advanced Malignant Neoplasm
        • +5 more
        • AMXI-5001:Dose Escalation Phase I
        • AMXI-5001:Dose Expansion Phase II
        • Phoenix, Arizona
        • +7 more
        Jul 18, 2022